Trade Mark Journal No.2026/014 3 April 2026

WO0000001898012 (5,10,42,44)

Office of origin: United States of America

Date of International Registration:21 March 2025
Date of designation in the UK: 21 March 2025
Image for mark 1898012 THE MESSAGE IS IN THE BLOOD

International priority date claimed: 24 September 2024 (United States of America) (98766338)
International priority date claimed: 24 September 2024 (United States of America) (98766340)
International priority date claimed: 24 September 2024 (United States of America) (98766341)
International priority date claimed: 24 September 2024 (United States of America) (98766342)
Class 5
Diagnostic kits consisting primarily of clinical diagnostic reagents and assays for cancer screening.
Class 10
Blood testing apparatus, namely, a biospecimen kit comprised of blood collecting tubes, test request form and biospecimen compliant packaging for shipping the tubes.
Class 42
Scientific research for medical purposes in the area of blood-based diagnostics, RNA, mRNA, cancer, genetic, and oncological diseases and disorders; structural and functional analysis of genomes; providing scientific research information in the field of blood-based diagnostics, RNA, mRNA, cancer, genetic and oncological diseases and disorders.
Class 44
Medical testing of blood for purposes of screening, detecting, diagnosing, and treating cancer, genetic, and oncological diseases and disorders; blood-based testing to determine the aggressiveness of a patient's cancer and prognosis on treatments including targeted therapies and immunotherapy; providing medical and scientific research information in the field of blood-based diagnostics, RNA, mRNA, cancer, genetic, and oncological diseases and disorders via a website.

Clifton Life Sciences LLC

Representative: Abion UK Limited, The Forum, St Paul’s, 33 Gutter Lane London EC2V 8AS UNITED KINGDOM